Over 256 women, age 21 to 65, with acquired mixed female sexual disorders participated in a 16-week randomized, placebo-controlled, double-blind study of Zestra, a topical botanical preparation. Routine outcome instruments measured efficacy and safety. Zestra was well tolerated. The only significant safety finding was mild-to-moderate genital burning seen only in Zestra-treated subjects (14.6%). Zestra provided significant desire, arousal, and treatment satisfaction benefits for a broadly generalized group of women with sexual difficulties.
No takes yet. Share an insight, caveat, or question.
Ferguson et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: